Mesoblast Ltd.

Mesoblast Ltd. is a clinical development company leveraging its proprietary core adult stem cell technologies, which include the Mesenchymal Precursor Cell (MPC) and culture-expanded Mesenchymal Stem Cell (MSC) platform technologies, Dental Pulp Stem Cells and expanded Hematopoietic Stem Cells. The company's cardiovascular and neurologic product pipeline is being developed in partnership with Teva Pharmaceutical Industries Ltd. Mesoblast Ltd's subsidiaries include Mesoblast Inc., Mesoblast International SA, Mesoblast Australia Pty Ltd and Mesoblast UK Ltd.

Expert Comments:

Marcel Wijma, The Daily Molecule (Van Leeuwenhoeck Research) (7/24/15)
"Mesoblast Ltd. announced that results of the Phase 2 trial of its intravenously delivered mesenchymal precursor cells (MPCs) for the treatment of type 2 diabetes have been published online ahead of full print in the peer-reviewed journal of the American Diabetes Association, Diabetes Care. . .the Phase 2 randomized, single-blind, placebo-controlled trial was conducted across 18 sites in the U.S. and evaluated the effects of a single intravenous infusion of 0.3, 1 or 2 million MPCs/kilogram or placebo over 12 weeks in 61 patients with a mean diabetes duration of 10 years."

Henry McCusker, Regenerative Medicine Investors (7/23/15)
"Mesoblast Ltd. today announced that results of the Phase 2 trial of its intravenously delivered mesenchymal precursor cells (MPCs) for the treatment of type 2 diabetes. . .the primary endpoint of safety was safe and well tolerated, with no treatment-related adverse events and no serious adverse events over the 12-week study period. There were no anti-human leukocyte antigen antibody immune responses against MPC donor antigens identified in any subject."

Katherine Genis, Edison Investment Research (7/23/15)
"Mesoblast Ltd.'s recent agreement with Celgene Corp., which entailed a net AU$58.5M equity purchase in return for first right of refusal on products in certain disease areas, provides Mesoblast with a capital injection and potential development/commercialization partner. Meanwhile, an imminent regulatory decision in Japan for MSC-100-IV in acute graft versus host disease could prove a significant share price catalyst; if approved, MSC-100-IV would be the company's first product to market."

Jason Kolbert, Maxim Group (7/23/15)
"Mesoblast Ltd. continues to show the versatility of its mesenchymal precursor cells (MPCs) with the publication of the results from the Phase 2 trial study of MPCs for the treatment of type 2 diabetes. . .the study evaluated the safety and efficacy of intravenously delivered MPCs in patients with type 2 diabetes. . .the data showed a positive safety profile and early signs of efficacy."

Jason Kolbert, Maxim Group (7/15/15)
"Trial results of Mesoblast Ltd.'s cell therapy product candidate for the treatment of congestive heart failure have been published in the latest edition of Circulation Research. . .recall that it is the results of the Phase 2 trial that formed the basis of the current pivotal trial with partner Teva Pharmaceutical Industries Ltd. According to our channel checks, the current program has been both positive and robust. Our understanding is that the trial is enrolling very well and that Teva is now talking about Revascor. We see this as an important net positive for Mesoblast."

Jason McCarthy, Maxim Group (7/2/15)
"We only need to look to Mesoblast Ltd.'s Prochymal stem cells for graft-versus-host disease to see the incredible opportunity that abounds in the oncology and oncology-related markets; Prochymal is saving pediatric lives today, and U.S. pivotal (bridging) studies are now planned for the U.S. marketplace. More impressive is the safety profile where safety with allogeneic stem cell therapy is just not an issue."

More Expert Comments

Experts Commenting on This Company

Kevin DeGeeter, Director, Equity Research Analyst – Ladenburg Thalmann
Katherine Genis, Analyst – Edison Investment Research
Christopher James, Managing Director, Senior Equity Research Analyst – Brinson Patrick Securities Corporation
Jason Kolbert, Senior Analyst – Maxim Group
Henry McCusker – Regenerative Medicine Investors
Henry McCusker, Founder and Director of Research – Scimitar Equity
Alain Vertes, Managing Director – NxR Biotechnologies GmbH
Marcel Wijma, Analyst – The Daily Molecule (Van Leeuwenhoeck Research), Van Leeuwenhoeck Research

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Mesoblast Ltd. Content